27
Sep
2022
XVIVO Perfusion’s CEO Dag Andersson has passed away
XVIVO Perfusion AB's (publ) board of directors announces that CEO Dag Andersson has suddenly passed away. The board…
Read moreNews Tag: English - Page 3
21
Sep
2022
XVIVO presents strategy for 2023-2027 at its Capital Markets Day
Today at the XVIVO digital Capital Markets Day, CEO Dag Andersson and other senior executives will present the company’s strategy to become global leader in the transplant industry. During the strategy period, the commercialization of XVIVO’s full product portfolio has the potential to transform the field of organ transplantation and accelerate XVIVO’s growth further.
Read more
20
Sep
2022
XVIVO granted Breakthrough Device Designation from the FDA for the Liver Assist device
XVIVO has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for their Liver Assist device, indicated for ex-vivo oxygenated machine perfusion for preservation of donor livers prior to transplantation. The FDA’s Breakthrough Device Program is intended to expedite the development and prioritize the regulatory review of certain medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions than previous therapies.
Read more
24
Aug
2022
XVIVO Capital Markets Day 2022
XVIVO invites to its digital Capital Markets Day, September 21, 2022. Dag Andersson, CEO, and members of the XVIVO management team will cover company strategy, financials and operations momentum. Dr. David McGiffin, Australia, will join as a guest speaker. He will present his experience with the XVIVO Heart technology as the coordinating principal investigator of the ANZ NIHP clinical trial.
Read more
01
Aug
2022
XVIVO enters into an agreement to acquire its Italian distributor – securing a unique business model
XVIVO Perfusion AB (publ) (“XVIVO” or the “Company”) has today signed an agreement to acquire 100 percent of the shares in Avionord S.r.l.’s machine and perfusion business (“Avionord M&P”) for a purchase price amounting to a maximum of EUR 12.0 million. Initial purchase price amounts to maximum EUR 9.6 million, whereof approximately 40 percent will be paid in cash and 60 per cent by issuance of new shares in XVIVO, with an additional potential earn-out payment of maximum EUR 2.4 million to be paid out in 2023. Completion of the acquisition is expected to take place during November 2022.
Read more